Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug [Yahoo! Finance]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Yahoo! Finance
Aardvark Therapeutics is developing a therapy designed to activate certain gut receptors to prompt satiety and suppress hunger. Image credit: Shiv Pahal via Shutterstock. · Pharmaceutical Technology · Shiv Pahal via Shutterstock. Jenna Philpott Thu, February 13, 2025 at 7:16 PM GMT+1 3 min read Aardvark Therapeutics has raised $94.2m in an initial public offering (IPO) to support the development of its hunger-suppressing drug ARD-101 for the rare disease Prader-Willi syndrome. The US-based biotech sold just under 5.9 million shares at $16 each. The pricing was at the lower end of the company's expected range, which was between $16 and $18 apiece, according to a 6 February SEC filing. Aardvark will trade on the Nasdaq stock exchange under the ticker symbol “AARD”. Aardvark is developing hunger-suppressing treatments for Prader-Willi syndrome and obesity-related conditions. Its lead candidate, ARD-101, is an oral TAS2R agonist designed to activate bitter taste recepto
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred LossesPR Newswire
- Soleno Therapeutics (SLNO) Valuation Check After Wolfe Research's Optimistic New Coverage and Stock Pop [Yahoo! Finance]Yahoo! Finance
- How Soleno Therapeutics' Audit Committee Leadership Transition At Soleno Therapeutics (SLNO) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNOPR Newswire
- Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026? [Yahoo! Finance]Yahoo! Finance
SLNO
Earnings
- 11/4/25 - Beat
SLNO
Sec Filings
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- SLNO's page on the SEC website